BOSTON--(BUSINESS WIRE)--Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain (the “Company”), announced today that it will present updated safety and efficacy data of CNTX-4975, the Company’s lead therapeutic candidate, at the 12th Annual PAINWeek National Conference taking place in Las Vegas, Nevada from September 4 – 8.
Full abstracts are available online at the PAINWeek Abstract Book. The poster presentation details are as follows:
Title: Efficacy of Intra-articular CNTX-4975 for Knee
Osteoarthritis (“OA”) Pain Varies With Radiographic Presence of OA in
the Opposite Knee
Session Title: POS-01
Poster Number: 95
Presentation Date & Time: Thursday, September 6, 6:30-8:30 p.m. PT
Location: Level 2, Condesa Commons
For additional information regarding PAINWeek, please visit the conference website: www.painweek.org.
Osteoarthritis (“OA”) is the most common form of arthritis, affecting approximately 30 million people in the United States according to the U.S. Centers for Disease Control, OA occurs when the protective cartilage on the ends of the bones wears down over time, and the bone around the joints harden and form edges. These changes cause pain, swelling and problems moving the joint. OA also causes an inflammatory process to occur in the affected joint, further damaging the cartilage. Although OA can damage the majority of joints in the body, it most commonly affects joints in the knees, hips, hands and spine. OA can cause pain severe enough that patients experience difficulty walking, climbing stairs or even rising from a chair. Despite currently available therapies, many patients opt for total joint replacement to manage the painful condition.
CNTX-4975, the Company’s lead product candidate, is a highly potent, ultra-pure, synthetic form of trans-capsaicin. CNTX-4975 is designed to be injected directly into the site of pain to provide rapid onset, large reduction and long duration of relief from moderate to severe joint pain without affecting touch sensibility or position sense. CNTX-4975 works by targeting the capsaicin receptor (TRPV1) to selectively and rapidly inactivate the local pain fibers transmitting signals to the brain. With a short half-life, CNTX-4975 is cleared from the body within 24 hours. This approach is designed to provide pain relief that can last for months until the ends of the local pain fibers regenerate, while maintaining normal sensation, such as touch, pressure and position, and without the risks of toxicities of non-steroidal anti-inflammatory drugs and injected corticosteroids, or the side effects, including abuse and addiction, associated with opioid treatments. In January 2018, CNTX-4975 was granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of pain associated with knee OA.
About Centrexion Therapeutics Corporation
The Company is focused on advancing the treatment of chronic moderate to severe pain with one of the largest, exclusively pain-focused pipelines of non-opioid, non-addictive product candidates in active development. The Company recognizes the needs of the 1.5 billion people living with chronic pain worldwide, and aims to develop new, safer and more effective therapies that overcome the limitations and challenges associated with current pain treatments. Founded by world-renowned leaders in drug development and well-funded by key investors, the Company is building a pain treatment powerhouse to address the substantial and growing global chronic pain epidemic. For more information about the Company, visit http://www.centrexion.com.